BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 3,818 shares of the business’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $83.88, for a total value of $320,253.84. Following the completion of the sale, the executive vice president now directly owns 94,634 shares of the company’s stock, valued at $7,937,899.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
George Eric Davis also recently made the following trade(s):
- On Monday, March 5th, George Eric Davis sold 2,105 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $79.04, for a total value of $166,379.20.
- On Thursday, February 1st, George Eric Davis sold 30,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.66, for a total value of $2,719,800.00.
BioMarin Pharmaceutical Inc. (NASDAQ BMRN) traded up $0.43 during midday trading on Tuesday, reaching $84.25. The company’s stock had a trading volume of 894,751 shares, compared to its average volume of 1,370,517. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.70 and a quick ratio of 2.12. BioMarin Pharmaceutical Inc. has a 52 week low of $77.04 and a 52 week high of $100.51. The firm has a market cap of $14,807.68, a PE ratio of -125.75 and a beta of 1.74.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, February 22nd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.06). BioMarin Pharmaceutical had a negative return on equity of 3.18% and a negative net margin of 8.91%. The business had revenue of $358.31 million for the quarter, compared to analyst estimates of $346.24 million. research analysts predict that BioMarin Pharmaceutical Inc. will post -0.71 earnings per share for the current year.
Several analysts have commented on the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $125.00 price objective (up from $119.00) on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Wedbush reaffirmed an “outperform” rating and set a $110.00 price objective on shares of BioMarin Pharmaceutical in a research note on Friday, December 22nd. SunTrust Banks upped their price objective on BioMarin Pharmaceutical to $130.00 and gave the company a “buy” rating in a research note on Monday, December 11th. Zacks Investment Research downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Wednesday, January 17th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Sunday, February 25th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $112.34.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ladenburg Thalmann Financial Services Inc. increased its position in BioMarin Pharmaceutical by 22.9% during the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,224 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 600 shares during the period. Glenmede Trust Co. NA increased its position in BioMarin Pharmaceutical by 3.7% during the 4th quarter. Glenmede Trust Co. NA now owns 17,520 shares of the biotechnology company’s stock worth $1,562,000 after purchasing an additional 622 shares during the period. First Manhattan Co. increased its position in BioMarin Pharmaceutical by 104.2% during the 4th quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 625 shares during the period. Commerce Bank grew its holdings in shares of BioMarin Pharmaceutical by 29.5% in the 4th quarter. Commerce Bank now owns 2,907 shares of the biotechnology company’s stock worth $259,000 after acquiring an additional 662 shares during the period. Finally, Pacer Advisors Inc. grew its holdings in shares of BioMarin Pharmaceutical by 14.0% in the 3rd quarter. Pacer Advisors Inc. now owns 6,066 shares of the biotechnology company’s stock worth $565,000 after acquiring an additional 744 shares during the period.
COPYRIGHT VIOLATION NOTICE: “BioMarin Pharmaceutical Inc. (BMRN) EVP Sells $320,253.84 in Stock” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/03/20/biomarin-pharmaceutical-inc-bmrn-evp-sells-320253-84-in-stock.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.